Clinical Applications of Monoclonal Antibodies
Author | : Ron Hubbard |
Publisher | : |
Total Pages | : 272 |
Release | : 2014-01-15 |
Genre | : |
ISBN | : 9781461315742 |
Download Clinical Applications of Monoclonal Antibodies Book in PDF, ePub and Kindle
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Clinical Applications Of Monoclonal Antibodies PDF full book. Access full book title Clinical Applications Of Monoclonal Antibodies.
Author | : Ron Hubbard |
Publisher | : |
Total Pages | : 272 |
Release | : 2014-01-15 |
Genre | : |
ISBN | : 9781461315742 |
Author | : National Research Council |
Publisher | : National Academies Press |
Total Pages | : 74 |
Release | : 1999-05-06 |
Genre | : Medical |
ISBN | : 0309173051 |
The American Anti-Vivisection Society (AAVS) petitioned the National Institutes of Health (NIH) on April 23, 1997, to prohibit the use of animals in the production of mAb. On September 18, 1997, NIH declined to prohibit the use of mice in mAb production, stating that "the ascites method of mAb production is scientifically appropriate for some research projects and cannot be replaced." On March 26, 1998, AAVS submitted a second petition, stating that "NIH failed to provide valid scientific reasons for not supporting a proposed ban." The office of the NIH director asked the National Research Council to conduct a study of methods of producing mAb. In response to that request, the Research Council appointed the Committee on Methods of Producing Monoclonal Antibodies, to act on behalf of the Institute for Laboratory Animal Research of the Commission on Life Sciences, to conduct the study. The 11 expert members of the committee had extensive experience in biomedical research, laboratory animal medicine, animal welfare, pain research, and patient advocacy (Appendix B). The committee was asked to determine whether there was a scientific necessity for the mouse ascites method; if so, whether the method caused pain or distress; and, if so, what could be done to minimize the pain or distress. The committee was also asked to comment on available in vitro methods; to suggest what acceptable scientific rationale, if any, there was for using the mouse ascites method; and to identify regulatory requirements for the continued use of the mouse ascites method. The committee held an open data-gathering meeting during which its members summarized data bearing on those questions. A 1-day workshop (Appendix A) was attended by 34 participants, 14 of whom made formal presentations. A second meeting was held to finalize the report. The present report was written on the basis of information in the literature and information presented at the meeting and the workshop.
Author | : Ron Hubbard |
Publisher | : Springer |
Total Pages | : 282 |
Release | : 1988 |
Genre | : Medical |
ISBN | : |
Immunology has come a long way in the hundred or so years since the general concepts were first enuciated by Metchnikoff, Ehrlich, Von Bebring and others, One of the landmarks in this progress was the invention and development of monoclonal antibody secreting hybridomas by Milstein and bis co-workers in Cambridge. Unlike most modern inventions of this importance that of monoclonal antibody production was made available to the scientific community tbroughout the world unimpeded by patent protection. This may explain tbe unusual rapidity witb which it has been applied to the benefit of mankind in general. This book, representing as it does the proceedings of tbe first International Symposium to be held on the clinical appli cations of monoclonal antibodies, shows just how much bas been achieved within the space of little more than a decade. The enormaus promise of monoclonal antibody technology, which became apparent soon after its discovery, has already progressed a long way towards fulfillment. The contributors to tbis volume, all of whom are actively engaged in monoclonal antibody development and application, represent the state of the art. Professor Vincent Marks V INTRODUCTION It has been some twelve years since the pioneering experiments of Köhler and Milstein led to the discovery of monoclonal antibodies. Single molecular species antiborlies with desired specificities could be produced by the fusion of antibody - producing cells with neoplastic cells.
Author | : Dirk J. Ruiter |
Publisher | : Springer Science & Business Media |
Total Pages | : 387 |
Release | : 2012-12-06 |
Genre | : Medical |
ISBN | : 9400932995 |
The development of monoclonal antibodies to human tumor associated antigens has greatly facilitated the application of immunohistochemical techniques to analyze surgically removed tissues. During the last few years this approach has been utilized by a progressively increasing number of investigators to analyze malignant cells. Although monoclonal antibodies to tumor associated antigens have not become yet routine reagents in immunopathology, they have provided new information which could not be obtained with conventional antisera or histochemical procedures. The following are representative examples. TUmor associated antigens have been identified which display a restricted distribution in normal tissues and therefore may represent useful markers for radio imaging and appropriate targets for immunotherapy. In spite of undetec table differences with conventional histopathological approaches hetero geneity has been found in the antigenic profile of tumor cells within a lesion, in autologous lesions removed from different anatomic sites from a given patient and in lesions removed from different patients. Phenotypes of tumor cells have been identified which correlate with the biology of tumor cells and with the clinical course of the disease. From a practical view point the use of monoclonal antibodies in immunopathology has enhanced interactions between pathologists and immunologists, as exemplified by the present book. Such interactions have contributed to the application of basic research to clinical problems. The chapter of this book discuss investigations performed with monoclonal antibodies to antigens expressed by various types of normal and malignant human cells.
Author | : Zhiqiang An |
Publisher | : John Wiley & Sons |
Total Pages | : 932 |
Release | : 2011-09-20 |
Genre | : Science |
ISBN | : 1118210263 |
70-chapter authoritative reference that covers therapeutic monoclonal antibody discovery, development, and clinical applications while incorporating principles, experimental data, and methodologies. First book to address the discovery and development of antibody therapeutics in their entirety. Most chapters contain experimental data to illustrate the principles described in them. Authors provide detailed methodologies that readers can take away with them and use in their own laboratories.
Author | : David J. King |
Publisher | : CRC Press |
Total Pages | : 262 |
Release | : 1998-11-27 |
Genre | : Medical |
ISBN | : 9780748404223 |
A valuable resource for researchers and workers in the fields of both pharmaceuticals and biotechnology as well as undergraduates in biochemistry, applied biology, biomedical sciences and pharmacy, this book compares established techniques of antibody production with the new. Antibody structure and the implications of antibody engineering are fully discussed, and a case study approach illustrates how antibodies are finding increasing use in the diagnosis and treatment of disease. The volume ends with commercial expression, purification and large-scale manufacture of antibodies and their future potential, particularly as therapeutic agents.
Author | : Martin Rosenberg |
Publisher | : Springer Science & Business Media |
Total Pages | : 414 |
Release | : 2012-12-06 |
Genre | : Medical |
ISBN | : 3642784321 |
A sample of the most exciting developments in the cloning, manipulation, expression and application of genetically-engineered monoclonal antibodies. This rapidly-evolving field has witnessed the PCR combinatorial cloning of vast immunological diversity, in vitro mutagenesis of MAbs, MAbs created by transgenic animals, novel expression systems in plants, animals and lower systems, as well as a rich variety of genetically modified MAbs as potential therapeutic agents. Leading scientists from academia and industry present their own findings as well as short reviews of these research areas.
Author | : Lara V. Marks |
Publisher | : Yale University Press |
Total Pages | : 345 |
Release | : 2015-06-28 |
Genre | : Medical |
ISBN | : 0300213522 |
This book is the first to tell the extraordinary yet unheralded history of monoclonal antibodies. Often referred to as Mabs, they are unfamiliar to most nonscientists, yet these microscopic protein molecules are everywhere, quietly shaping our lives and healthcare. Discovered in the mid-1970s in the laboratory where Watson and Crick had earlier unveiled the structure of DNA, Mabs have radically changed understandings of the pathways of disease. They have enabled faster, cheaper, and more accurate clinical diagnostic testing on a vast scale. And they have played a fundamental role in pharmaceutical innovation, leading to such developments as recombinant interferon and insulin, and personalized drug therapies such as Herceptin. Today Mabs constitute six of the world’s top ten blockbuster drugs and make up a third of new introduced treatments. Lara V. Marks recounts the risks and opposition that a daring handful of individuals faced while discovering and developing Mabs, and she addresses the related scientific, medical, technological, business, and social challenges that arose. She offers a saga of entrepreneurs whose persistence and creativity ultimately changed the healthcare landscape and brought untold relief to millions of patients. Even so, as Marks shows, controversies over Mabs remain, and she examines current debates over the costs and effectiveness of these innovative drugs.
Author | : Brian A. Baldo |
Publisher | : Springer |
Total Pages | : 623 |
Release | : 2016-08-12 |
Genre | : Medical |
ISBN | : 3319304720 |
This long overdue title provides a comprehensive, up-to-date, state-of-the art review of approved biologic therapies, with coverage of mechanisms of action, Indications for therapy, immunogenicity and a detailed examination of adverse effects and safety of the many and diverse therapeutic agents presented in a total of 13 chapters. It is predicted that by 2016, biologics will make up half of the world's 20 top-selling drugs and by 2018, biologic medicine sales will account for almost half of the world's 100 biggest selling drugs. Recombinant proteins dominate the growing list of the more than 200 approved biotherapeutic agents with targeted antibodies, fusion proteins and receptors; cytokines; hormones; enzymes; proteins involved in blood-clotting, homeostasis and thrombosis; vaccines; botulinum neurotoxins; and, more recently, biosimilar preparations, comprising the majority of approved biologics. Written with clinicians, other health care professionals, and researchers in mind, Safety of Biologics Therapy examines, in a single volume, the full range of issues surrounding the safety of approved biologic therapies. A good understanding of the risks and safety issues of modern biologics therapy is increasingly being demanded of all those connected with their development, handling, prescribing, administration and subsequent patient management. In addition to being of great value to clinicians in all branches of medicine, and to nurses, pharmacists and researchers, this book will prove invaluable for students taking undergraduate and graduate courses in the above disciplines and in the biomedical sciences.
Author | : Cheng Liu |
Publisher | : John Wiley & Sons |
Total Pages | : 723 |
Release | : 2016-12-09 |
Genre | : Medical |
ISBN | : 1118940628 |
Addressing a significant need by describing the science and process involved to develop biosimilars of monoclonal antibody (mAb) drugs, this book covers all aspects of biosimilar development: preclinical, clinical, regulatory, manufacturing. • Guides readers through the complex landscape involved with developing biosimilar versions of monoclonal antibody (mAb) drugs • Features flow charts, tables, and figures that clearly illustrate processes and makes the book comprehensible and accessible • Includes a review of FDA-approved mAb drugs as a quick reference to facts and useful information • Examines new technologies and strategies for improving biosimilar mAbs